Publications by authors named "Yongya Kim"
Article Synopsis
- Tau neurofibrillary tangles are a key indicator of Alzheimer's disease, and while their association with certain types of tau seeds is unclear, research shows that specific tau seeds (3R/4R) can be quantified using RT-QuIC assays in brain tissue.
- These assays reveal that tau seeding activity can be detected before any visible tau deposits appear, indicating a possible early biomarker for Alzheimer's progression, especially in late disease stages.
- The study also found that 3R/4R tau seeds are not only prevalent in Alzheimer's patients but also present in other neurodegenerative conditions like Lewy body disease, with notable gender differences in tau levels, particularly in more advanced disease stages.
Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies.
J Neuropathol Exp Neurol
November 2022
3R/4R-tau species are found in Alzheimer disease (AD) and ∼50% of Lewy body dementias at autopsy (LBD+tau); 4R-tau accumulations are found in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Digital image analysis techniques can elucidate patterns of tau pathology more precisely than traditional methods but repeatability across centers is unclear. We calculated regional percentage areas occupied by tau pathological inclusions from the middle frontal cortex (MFC), superior temporal cortex (STC), and angular gyrus (ANG) from cases from the University of Pennsylvania and the University of California San Diego with AD, LBD+tau, PSP, or CBD (n = 150) using QuPath.
View Article and Find Full Text PDFObjective: The purpose of this study was to determine the sensitivity and specificity of α-synuclein seed amplification assay (αSyn-SAA) in antemortem and postmortem cerebrospinal fluid (CSF) of autopsy-confirmed patients with different distributions of pathological αSyn, co-pathologies, and clinical diagnoses.
Methods: The αSyn-SAA was used to test antemortem CSF samples from 119 subjects with a variety of clinical syndromes and standardized neuropathological examinations from Oregon Health and Science University (OHSU) and University of California San Diego (UCSD; 56 additional postmortem CSF samples available). The αSyn-SAA was also applied to frontal cortex and amygdala homogenates.